Literatur Review: Cysteamine Terapi Terkini Hiperpigmentasi yang Menjanjikan
DOI:
https://doi.org/10.57214/jka.v9i1.745Keywords:
Cysteamine, Hyperpigmentation, Melasma, Lentigo, Depigmenting agentAbstract
Cysteamine, an aminothiol compound naturally produced in human cells, is emerging as an effective depigmenting agent to treat hyperpigmentation conditions such as melasma and lentigo. Although hydroquinone has become the gold standard in the treatment of melasma, its long-term use can cause serious side effects. Cysteamine offers a safer and effective alternative with mechanisms of action that include inhibition of the tyrosinase enzyme, increased glutathione levels, and keratolytic effects. Various studies have shown that cysteamine 5% cream is not only better tolerated compared to Kligman's Formula, but also shows equivalent or better ability in reducing Modified Melasma Area and Severity Index (mMASI) scores. In addition, cysteamine was also effective in treating lentigo, with significant results in the reduction of hyperpigmentation. Although there are tolerance-related challenges, especially the unpleasant odor, the potential efficacy and good safety profile make cysteamine a promising option in the treatment of hyperpigmentation. Further research is needed to optimize formulations and explore combination therapies for better results.
References
Cassiano, D. P., Lima, P. B., Dias, J. A. F., Esposito, A. C. C., & Miot, H. A. (2022). Efficacy and safety of the 5% cysteamine cream left in overnight for facial melasma: A pilot study. Surgical & Cosmetic Dermatology, 14(0), 1–3. https://doi.org/10.5935/scd1984-8773.2022140160
Dos Santos-Neto, A. G., da Silva, Í. C. V., Melo, C. R., Santana, A. A. M., & de Albuquerque-Junior, R. L. C. (2022). Is cysteamine use effective in the treatment of melasma? A systematic review and meta-analysis. Dermatologic Therapy, 35(12), e15961. https://doi.org/10.1111/dth.15961
Karrabi, M., Mansournia, M. A., Sharestanaki, E., Abdollahnejad, Y., & Sahebkar, M. (2021). Clinical evaluation of efficacy and tolerability of cysteamine 5% cream in comparison with tranexamic acid mesotherapy in subjects with melasma: A single-blind, randomized clinical trial study. Archives of Dermatological Research, 313(7), 539–547. https://doi.org/10.1007/s00403-020-02133-7
Kasraee, B., Mansouri, P., & Farshi, S. (2018). Significant therapeutic response to cysteamine cream in a melasma patient resistant to Kligman's formula. Journal of Cosmetic Dermatology, 18(1), 265–267. https://doi.org/10.1111/jocd.12837
Lima, P. B., Dias, J. A. F., Cassiano, D., Esposito, A. C. C., Bagatin, E., Miot, L. D. B., & Miot, H. A. (2020). A comparative study of topical 5% cysteamine versus 4% hydroquinone in the treatment of facial melasma in women. International Journal of Dermatology, 59(12), 1531–1536. https://doi.org/10.1111/ijd.15146
Mathe, N., Balogun, M., & Yoo, J. (2021). A case report on the use of topical cysteamine 5% cream in the management of refractory postinflammatory hyperpigmentation (PIH) resistant to triple combination cream (hydroquinone, topical corticosteroids, and retinoids). Journal of Cosmetic Dermatology, 20(1), 204–206. https://doi.org/10.1111/jocd.13755
Nguyen, J., Remyn, L., Chung, I. Y., Honigman, A., Gourani-Tehrani, S., Wutami, I., Wong, C., Paul, E., & Rodrigues, M. (2021). Evaluation of the efficacy of cysteamine cream compared to hydroquinone in the treatment of melasma: A randomised, double-blinded trial. Australasian Journal of Dermatology, 62(1), e41–e46. https://doi.org/10.1111/ajd.13432
Saki, N. (2021). Stabilized cysteamine 5% cream for the treatment of senile lentigo. SKIN: The Journal of Cutaneous Medicine, 5(Suppl.), s89. https://doi.org/10.25251/skin.5.supp.89
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Jurnal Kesehatan Amanah
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
